Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
New hope for children with aggressive form of cancer

New hope for children with aggressive form of cancer

Children with an aggressive form of cancer are being given new hope in a world-first trans-Atlantic clinical trial that will test a new three-part treatment.

The study, involving doctors and cancer scientists in Southampton, America and Germany, will boost the body’s immune system to kill off neuroblastoma, one of the most common childhood cancers.

The Phase 1 trial is funded by UK charities Solving Kids’ Cancer (Europe), JACK and US charities Solving Kids’ Cancer and Band of Parents. It will be one of many to be conducted at the University of Southampton’s Centre for Cancer Immunology, which is the UK’s first and only centre dedicated to cancer immunology research. The centre recently opened at University Hospital Southampton, thanks to the University’s £25m fundraising campaign.

Neuroblastoma affects around 100 children – mostly under the age of five – in the UK every year and develops from immature nerve cells. It usually starts as a tumour in the abdomen or chest, however, in many children, it spreads to other places in the body such as the bones and bone marrow.

In those cases, less than half of patients are cured despite intensive treatment which includes surgery, chemotherapy, radiotherapy and stem cell transplants.

More recently, a form of immunotherapy known as anti-GD2, which uses antibodies to lock onto cancer cells so the immune system can find, fight and destroy them, has shown the potential to improve survival rates.

This new study, led by Dr Juliet Gray, Associate Professor of Paediatric Oncology at the University of Southampton, involves combining mIBG, a special form of targeted radiotherapy which delivers radioactive iodine directly to neuroblastoma cells, with two different antibody therapies for the first time.

One of these therapies, Nivolumab, has shown exciting results in adult cancers. It blocks a harmful protein called PD-1 and gives patients’ own immune cells a boost so that they can be set free to kill tumour cells.

The researchers will give Nivolumab alongside the currently-used anti-GD2 to target specific cancer cells while protecting normal healthy cells.

The trial will be run from four centres – the University of Southampton’s Centre for Cancer Immunology, UCH, Madison Children’s Hospital, Wisconsin, and the University of Greifswald, Germany. It is also the first trial to be sponsored by University Hospital Southampton NHS Trust.

“Immunotherapy with anti-GD2 has been shown to increase the number of children with neuroblastoma who stay in remission and has become a standard component of treatment – but sadly a large number of children still relapse and die from their disease,” explained University of Southampton’s Dr Gray who is also a consultant paediatric oncologist at Southampton Children’s Hospital.

“Work in the laboratory has shown that combining these types of antibodies with radiotherapy is potentially a very powerful way of eradicating neuroblastoma tumours and these three different therapies appear to work together to generate strong, protective immunity to the tumour.”

She added: “This trans-Atlantic trial will be the first time they have been tested together and we are hopeful the combination of treatments will substantially improve the cure rate of children with this form of cancer.”

Stephen Richards, CEO of Solving Kids’ Cancer (Europe), said: “Cutting-edge clinical trials offer real hope for children with high-risk neuroblastoma and their families. The numbers of children affected are small, so funding collaborative international research is the only way we will improve survival rates and find a cure for this devastating disease.”

The researchers plan to give an initial course of mIBG-targeted radiotherapy followed by Nivolumab and anti-GD2 over a period of six months. Although the initial stages of the treatment process will require children to be in hospital, it is hoped that the therapy will be well tolerated and will eventually be delivered largely on an outpatient basis.

The trial’s objective is to ensure the combination is safe to deliver to children with neuroblastoma in order to develop further studies to compare it with current treatments.

Source:

https://www.southampton.ac.uk/news/2018/10/trans-atlantic-trial.page

Tagged with:

About author

Related Articles